RXII RXi Pharmaceuticals Corporation

0.57
-0.0001  -0%
Previous Close 0.57
Open 0.57
Price To book 1.52
Market Cap 12.61M
Shares 22,127,000
Volume 90,217
Short Ratio 1.24
Av. Daily Volume 912,257

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 final readout due 2H 2017.
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2 first cohort data due 2Q 2017. Full data due 2H 2017.
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2 enrollment of first two cohorts has been completed. Third cohort ongoing.
RXI-109-1501
Retinal scarring
Phase 2 complete.
(RXI-109-1401)
Recurrence of keloids after keloid revision surgery
Phase 2 complete.
(RXI-109-1301)
Anti-scarring

Latest News

  1. RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum
  2. PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology
  3. Edited Transcript of RXII earnings conference call or presentation 11-May-17 8:30pm GMT
  4. RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
  5. RXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017
  6. RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
  7. RXi Pharmaceuticals Corporation Selected to Present at the Cavendish Global Health Impact Forum
  8. RXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
  9. RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting
  10. RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes
  11. The Life Sciences Report Examines RXi Pharmaceuticals Receiving Japanese Patent for RNAi Platform
  12. RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: 2016 By the Numbers : April 3, 2017
  13. RXi Pharmaceuticals to Present at the American Association for Cancer Research Annual Meeting
  14. RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights
  15. RXi Pharma Derma Drug Secures Japanese Patent
  16. RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
  17. RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum
  18. RXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference
  19. RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March 30, 2017